SCHEDULE 13G/A: Adage Capital Management Discloses 1.98% Passive Stake in Syros Pharmaceuticals

Adage Capital Management, L.P. and its affiliates have reported a 1.98% beneficial ownership stake in Syros Pharmaceuticals, Inc. as of December 31, 2024, held for investment purposes.

Summary

• Adage Capital Management, L.P., along with Robert Atchinson and Phillip Gross, are the reporting persons for this Schedule 13G filing.
• The filing pertains to their beneficial ownership of common stock, par value $0.001 per share, of Syros Pharmaceuticals, Inc.
• As of December 31, 2024, the reporting persons collectively beneficially own 531,914 shares of Syros Pharmaceuticals' common stock.
• This ownership represents 1.98% of the total outstanding common stock of Syros Pharmaceuticals, Inc.
• The percentage is calculated based on 26,832,457 shares of common stock outstanding as of October 24, 2024, as reported in Syros's Quarterly Report on Form 10-Q filed on October 31, 2024.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 5

Explanation: The document is a factual regulatory filing disclosing beneficial ownership. It does not contain information that would inherently lead to a positive or negative sentiment, although the presence of a known institutional investor can be mildly reassuring.

Positives

• The disclosure indicates that a notable institutional investor, Adage Capital Management, L.P., maintains a stake in Syros Pharmaceuticals, which can be viewed as a vote of confidence in the company's long-term prospects.

Future Outlook

This Schedule 13G filing is a disclosure of beneficial ownership and does not contain any forward-looking statements or guidance regarding Syros Pharmaceuticals, Inc.'s future performance or the reporting persons' future investment intentions beyond the passive nature of their current holding.

Management Comments

• "The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11."

Industry Context

This filing is a routine regulatory disclosure by an institutional investor, indicating their passive stake in a biotechnology company. It reflects ongoing institutional investment activity within the pharmaceutical sector but does not provide broader industry trends or competitive analysis.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional holder's passive stake in the company.

Key Dates

Keywords

Syros Pharmaceuticals, Adage Capital Management, beneficial ownership, Schedule 13G, common stock, institutional investment, SYRS